Evidence map›Paper›PMID 28854223›Full record

ArticlePloS one2017

Therapeutic potential of tonsil-derived mesenchymal stem cells in dextran sulfate sodium-induced experimental murine colitis.

Yeonsil Yu, Eun Mi Song, Ko Eun Lee, Yang-Hee Joo, Seong-Eun Kim, Chang Mo Moon, Ha Yeong Kim, Sung-Ae Jung, Inho Jo

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yeonsil YuDepartment of Molecular Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Eun Mi SongDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Ko Eun LeeDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Yang-Hee JooDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Seong-Eun KimDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Chang Mo MoonDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Ha Yeong KimDepartment of Molecular Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Sung-Ae JungDepartment of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Inho JoDepartment of Molecular Medicine, College of Medicine, Ewha Womans University, Seoul, South Korea.
Ewha Womans University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic potential of tonsil-derived mesenchymal stem cells (TMSC) prepared from human tonsillar tissue has been studied in animal models for several diseases such as hepatic injury, hypoparathyroidism, diabetes and muscle dystrophy. In this study, we examined the therapeutic effects of TMSC in a dextran sulfate sodium (DSS)-induced colitis model. TMSC were injected in DSS-induced colitis mice via intraperitoneal injection twice (TMSC[x2]) or four times (TMSC[x4]). Control mice were injected with either phosphate-buffered saline or human embryonic kidney 293 cells. Body weight, stool condition and disease activity index (DAI) were examined daily. Colon length, histologic grading, and mRNA expression of pro-inflammatory cytokines, interleukin 1β (IL-1β), IL-6, IL-17 and tumor necrosis factor α, and anti-inflammatory cytokines, IL-10, IL-11 and IL-13, were also measured. Our results showed a significant improvement in survival rates and body weight gain in colitis mice injected with TMSC[x2] or TMSC[x4]. Injection with TMSC also significantly decreased DAI scores throughout the experimental period; at the end of experiment, almost complete reversal of DAI scores to normal was found in colitis mice treated with TMSC[x4]. Colon length was also significantly recovered in colitis mice treated with TMSC[x4]. However, histopathological alterations induced by DSS treatment were not apparently improved by injection with TMSC. Finally, treatment with TMSC[x4] significantly reversed the mRNA levels of IL-1β and IL-6, although expression of all pro-inflammatory cytokines tested was induced in colitis mice. Under our experimental conditions, however, no apparent alterations in the mRNA levels of all the anti-inflammatory cytokines tested were found. In conclusion, our findings demonstrate that multiple injections with TMSC produced a therapeutic effect in a mouse model of DSS-induced colitis.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsBody WeightCell- and Tissue-Based TherapyChildColitisDextran SulfateDisease Models, AnimalGene Expression RegulationHEK293 CellsHumansInjections, IntraperitonealInterleukin-10Interleukin-11Interleukin-13Interleukin-17Dextran SulfateIL10 protein, mouseIL1B protein, mouseInterleukin-10Interleukin-11Interleukin-13Interleukin-17Interleukin-1betaInterleukin-6interleukin-6, mouseTumor Necrosis Factor-alpha

Identifiers

PMID28854223
PMCPMC5576698
OpenAlexW2752047530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.